NSE - Delayed Quote INR
Wanbury Limited (WANBURY.NS)
At close: 3:29 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
5,604,726.00
5,756,498.00
4,996,469.00
5,072,355.00
3,871,025.00
--
Cost of Revenue
2,838,595.00
3,026,306.00
3,034,423.00
3,058,726.00
2,262,080.00
--
Gross Profit
2,766,131.00
2,730,192.00
1,962,046.00
2,013,629.00
1,608,945.00
--
Operating Expense
2,221,196.00
2,160,476.00
1,854,172.00
1,722,195.00
1,461,614.00
--
Operating Income
544,935.00
569,716.00
107,874.00
291,434.00
147,331.00
--
Net Non Operating Interest Income Expense
-309,843.00
-291,811.00
-213,936.00
-199,415.00
-226,729.00
--
Pretax Income
523,840.00
563,373.00
-102,868.00
811,277.00
-124,057.00
--
Tax Provision
786.00
3,810.00
1,090.00
-3,462.00
2,000.00
--
Net Income Common Stockholders
523,054.00
559,563.00
-103,958.00
814,739.00
-126,057.00
--
Diluted NI Available to Com Stockholders
523,054.00
559,563.00
-103,958.00
814,739.00
-126,057.00
--
Basic EPS
15.99
17.10
-3.18
25.29
-5.04
--
Diluted EPS
15.77
16.89
-3.18
25.21
-5.04
--
Basic Average Shares
32,631.34
32,722.98
32,691.20
32,215.79
25,006.19
--
Diluted Average Shares
33,299.64
33,129.84
32,691.20
32,312.64
25,006.19
--
Rent Expense Supplemental
26,205.00
--
7,672.00
15,180.00
29,057.00
26,205.00
Total Expenses
5,059,791.00
5,186,782.00
4,888,595.00
4,780,921.00
3,723,694.00
--
Net Income from Continuing & Discontinued Operation
523,054.00
559,563.00
-103,958.00
814,739.00
-126,057.00
--
Normalized Income
267,869.47
305,723.36
-99,801.40
95,146.00
-100,767.40
--
Interest Income
3,604.00
--
4,157.00
6,693.00
4,019.00
3,604.00
Interest Expense
309,843.00
291,811.00
213,936.00
206,108.00
230,748.00
--
Net Interest Income
-309,843.00
-291,811.00
-213,936.00
-199,415.00
-226,729.00
--
EBIT
833,683.00
855,184.00
111,068.00
1,017,385.00
106,691.00
--
EBITDA
965,029.00
985,490.00
234,913.00
1,131,883.00
204,232.00
--
Reconciled Cost of Revenue
2,838,595.00
3,026,306.00
3,034,423.00
3,058,726.00
2,262,080.00
--
Reconciled Depreciation
131,346.00
130,306.00
123,845.00
114,498.00
97,541.00
--
Net Income from Continuing Operation Net Minority Interest
523,054.00
559,563.00
-103,958.00
814,739.00
-126,057.00
--
Total Unusual Items Excluding Goodwill
255,568.00
255,568.00
-5,938.00
719,593.00
-36,128.00
--
Total Unusual Items
255,568.00
255,568.00
-5,938.00
719,593.00
-36,128.00
--
Normalized EBITDA
709,461.00
729,922.00
240,851.00
412,290.00
240,360.00
--
Tax Rate for Calcs
0.00
0.00
0.00
--
0.00
--
Tax Effect of Unusual Items
383.47
1,728.36
-1,781.40
--
-10,838.40
--
3/31/2020 - 1/29/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
688506.SS Sichuan Biokin Pharmaceutical Co.,Ltd.
195.80
-0.82%
4574.T Taiko Pharmaceutical Co.,Ltd.
385.00
-1.03%
BROOKS.NS Brooks Laboratories Limited
138.10
-4.99%
RPGLIFE.NS RPG Life Sciences Limited
2,594.60
-5.65%
WINDLAS.NS Windlas Biotech Limited
948.85
-5.39%
SUVEN.NS Suven Life Sciences Limited
114.37
-7.14%
ASTRAZEN.NS AstraZeneca Pharma India Limited
7,190.60
-2.73%
JBCHEPHARM.NS J. B. Chemicals & Pharmaceuticals Limited
1,900.45
-0.29%
T14.SI Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
2.4700
+0.41%
AJANTPHARM.NS Ajanta Pharma Limited
2,977.40
-5.19%